Member Info for RayPointer

At 8% increase per day it will be 38p after 20 trading days LOL
Confirmation bias in action

I hope you don't masticate in public nom

Lindy begins speaking at about 15:50 minutes into the video

IMO the moditope patents are really quite specific

a) citrullinated proteins as targets for the treatment of cancer
b) homocitrullinated proteins as targets for the treatment of cancer

Sure, big pharma could find other SIPTMs (stress induced post translational modifications) that are promising but if you google this you find Lindy's work and not much else, so Lindy appears to be ahead of the game in this approach.

Have a look at Lindy talking about moditope here and you may begin to understand what an important breakthrough this may prove to be.

https://www.youtube.com/watch?v=CXyPYib5JWc

ATB

It could well be that any progress report issued by either party needs to be agreed by both parties and maybe issued as a coordinated joint statement.
IMO we are unlikely to get a blow by blow account of this collaboration.

Here's an introduction to AI in healthcare

https://en.wikipedia.org/wiki/Artificial_intelligence_in_healthcare

Interesting to see that IBM, Google, Microsoft and Intel are all working in this area

England 660 for 1 against India

Ruck

I have always said that we need to expect delays.
These are not normal projects.
Having said that, I do expect the SCIB1 combo trial to begin soon if not bang on the end of June. The main obstacle was regulatory approval and presumably we are now into the logistics of starting the trail.

Hope your dad is improving.

Here's what Lindy said about neo-antigens in that famous article (at least on this BB)

"The major disadvantage of designing vaccines targeting
neo-antigens is that patient-specific vaccines are expensive.
Furthermore, there is a high risk of tumour heterogenicity,
with regions of outgrowth that do not express the target
neo-antigen. "

Here's the link to Lindy's and Ruhul's article again

http://www.portlandpresspublishing.com/sites/default/files/biochemist/Biochemist%20Immunology%20issue/BioFEB19Web_Choudhury%29.pdf

And here's an explanation of tumour heterogeneity

https://en.wikipedia.org/wiki/Tumour_heterogeneity

http://www.denator.com/heat-stabilization/who/user-stories/prof-peter-james

I think this is the professor who advises on biotechnology for the Vulpes fund.

12 months plus to conduct due diligence on Scancell including meeting with RG and LD.

Vulpes had 20 to 25 investment ideas and Scancell was the final choice.

Note the Sweden connection as well.

https://www.proactiveinvestors.co.uk/companies/news/220600/scancell-exploring-new-frontiers-in-cancer-research-220600.html

See inflexion points

Five patients data early 2020
All patients data towards the end 2020
All patients 1 year data towards the end 2021

Ruck IMO

Improve response rates of CIs - Immunobody
SCIB1, SCIB2 and more to come

Provide superior treatments stand alone - Moditope
Modi1, Modi2, possibly Modi1/2 in combination (maybe Modi3)

Treat the non-responders - Both and also possibly TCR (Biontech)
TCR using moditope targets may be the best option for patients with weak immune repsonses

Yes, and for the 2020 AGM perhaps Wild will bring his cask

There's more than one Diggle apparently

https://www.theedgemarkets.com/article/investing-family-wealth

The bit about how the fund was named Vulpes is interesting.

It would have been quicker through Milan

I am driving back from sunny Italy today. I will be passing through Basel later today with my Scancell scarf trailing from the car window lol

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837657/

This article tends to suggest that metabolism plays a big role in maintaining the effectiveness of the TCell population.
Biontech may have a handle on this in their TCR technology. Clone only the fittest TCells.

An interesting article C7.
It would be interesting to know if activation of TCells actually plays a role in revival of tired cells. Do activated cells get a new lease of life and is this also passed on in clonal expansion?

Thanks Wild
A good post from a man in a camper van!

I simply could not put a value on it. There are far too many variables.
Timescales, results of trials, sentiment of big pharma towards cancer vaccines to name just 3.
What we could also see is a big pharma bod or bods waking up one morning and thinking "we must buy Scancell". The purchase of Juno and kite were IMO emotive buys. 1 success in the right area (Car-T or TCR) and the purchaser thinks " I am now in the race". What happens if and when cancer vaccines becomes the right area to be in?
Well Ugur Sahin is thinking that way, IRA Mellman ditto and James Allison diito and so are numerous other scientist members of the Scancell fan club.